A Trial of 10 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia

NCT05227690 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

385

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia

Interventions

DRUG: Placebo
DRUG: Emraclidine 10 mg
DRUG: Emraclidine 30 mg

Sponsor

AbbVie